Profile of temsirolimus in the treatment of advanced renal cell carcinoma.

Onco Targets Ther · 2010 · PMC2962305 · PMID 21049085

Europe PMC DOI

hedged sentences

0.0014

closest p · 0.0× alpha

0.2000

boldest claim

The sentences

highly significantP = 0.0014actually significant

The difference was highly significant ( P = 0.0014).

also in 132,142 other papers

did not reach statistical significanceP = 0.2not close (p > 0.1)

The results of this analysis presented at the 2008 ASCO Annual Meeting showed a difference in OS of 10.4 with nephrectomy vs 11.5 months without nephrectomy, but the difference did not reach statistical significance ( P = 0.2). 9 With IFN treatment a slight benefit for OS was seen, with nephrectomy patients surviving 7.8 months after nephrectomy vs 6.2 months without nephrectomy.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.